title: Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency.
abstract: The clinical course of a 9-year-old diagnosed with attention-deficit hyperactivity disorder, obsessive-compulsive disorder, and Tourette's disorder and treated with a combination of methylphenidate, clonidine, and fluoxetine is described. The patient experienced over a 10-month period, signs and symptoms suggestive of metabolic toxicity marked by bouts of gastrointestinal distress, low-grade fever, incoordination, and disorientation. Generalized seizures were observed, and the patient lapsed into status epilepticus followed by cardiac arrest and subsequently expired. At autopsy, blood, brain, and other tissue concentrations of fluoxetine and norfluoxetine were several-fold higher than expected based on literature reports for overdose situations. The medical examiner's report indicated death caused by fluoxetine toxicity. As the child's adoptive parents controlled medication access, they were investigated by social welfare agencies. Further genetic testing of autopsy tissue revealed the presence of a gene defect at the cytochrome P450 CYP2D locus, which results in poor metabolism of fluoxetine. As a result of this and other evidence, the investigation of the adoptive parents was terminated. This is the first report of a fluoxetine-related death in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism. Issues relevant to child and adolescent psychopharmacology arising from this case are discussed.
authors.affiliation: Department of Psychiatry, University of Cincinnati, Ohio 45267, USA. salleefr@email.uc.edu
authors.forename: F R
authors.initials: FR
authors.lastname: Sallee
authors.forename: C L
authors.initials: CL
authors.lastname: DeVane
authors.forename: R E
authors.initials: RE
authors.lastname: Ferrell
mesh_terms: D000982:Antipruritics / Q000378:metabolism / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000097:blood / Q000188:drug therapy; D002648:Child; D019389:Cytochrome P-450 CYP2D6 / Q000172:deficiency / Q000235:genetics*; D015259:Dopamine Agents / Q000378:metabolism / Q000627:therapeutic use; D004832:Epilepsy, Absence / Q000097:blood / Q000188:drug therapy; D017809:Fatal Outcome; D005473:Fluoxetine / Q000378:metabolism / Q000506:poisoning*; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000378:metabolism / Q000627:therapeutic use; D011110:Polymorphism, Genetic / Q000235:genetics*; D019338:Polypharmacy; D011398:Promethazine / Q000378:metabolism / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000378:metabolism / Q000506:poisoning*; D005879:Tourette Syndrome / Q000097:blood / Q000188:drug therapy
chemical_list: D000982:Antipruritics; D019389:Cytochrome P-450 CYP2D6; D015259:Dopamine Agents; D005473:Fluoxetine; D008774:Methylphenidate; D011398:Promethazine; D017367:Selective Serotonin Reuptake Inhibitors